Viking Therapeutics experienced a 38% drop in share prices following disappointing mid-stage trial results for its obesity treatment VK2735, which reported only a 12.2% mean weight loss. The unfavorable market reaction highlights skepticism regarding the drug's future amid increasing competition from Novo Nordisk and Eli Lilly, both of which are solidifying their dominance in the obesity and diabetes markets. While Novo Nordisk faces its own setbacks with a revised sales outlook, it continues to pursue strategic acquisitions and partnerships, leaving Viking struggling to maintain relevance in a rapidly evolving space.
“Viking Therapeutics · is developing · VK2735 · true”
“Novo Nordisk · has achieved · commercial success · tremendous”
“Novo Nordisk · has suffered · growth trajectory · recently”
“Novo Nordisk · revised · sales and profit outlook · for the year”
“U.S. market · pressure · NVO’s position · in obesity and diabetes markets”
“Eli Lilly · has captured · market share · in obesity and diabetes”
“CagriSema · met the primary endpoint of · statistically significant weight loss · in two late-stage studies”
“CagriSema · is planned for · regulatory submission · in 2026”
“NVO · is developing · oral and subcutaneous formulations · of amycretin”
“Novo Nordisk · acquired · Inversago Pharmaceuticals · in 2023”
“Novo Nordisk · signed · a $2.2 billion deal · with Septerna”
“Eli Lilly · is investing · in obesity · broadly”
